The Orange, California-based biotechnology company, founded in 2015 by Fauad Hasan, Mike Jarpe, Susan Abushakra, and Wajdie Ahmad, is focused on developing a botulinum neurotoxin to treat muscle hyperactivity, which is the root cause of musculoskeletal pain in both post-surgical and non-surgical settings. The company's neurotoxin offers patients a long-acting, non-opioid local muscle relaxant without the side effects of currently marketed products, addressing the unmet needs of patients with muscle hyperactivity.